and development of antibodies (Woodruff, McBride and Dunbar, 1974) . Recent work suggests that given orally in large doses, BCG maintains some of the anti-tumour effect seen after parenteral injection (Falk, Mann and Langer, 1973) . Similarly, antilymphocyte serum has been shown to prolong skin allograft survival after oral administration, (Seifert, Ring and Brendel, 1974) . Oral administration of drugs and vaccines would be advantageous and we therefore studied the effects of oral C. parvum on tumour growth, spleen size and antibody formation in mice.
MATERIALS AND METHODS
Age-matched syngeneic female C57/B1 mice (Olac) wl-ere used. Lew-is lung carcinoma which originated spontaneously as a carcinoma of the lung of a C57/B1 mouse at the Wistar Institute in 1951 (Sugiura and Stock, 1955) was implanted subcutaneously as a 04-ml homogenate in the lower flank.
It is a rapidly growing epidermoid carcinoma which wAhen implanted subcutaneously metastasizes to the lung (Simpson-Herren, Sanford and Holmquist, 1974) . Cells are released from the primary tumour 6 days after implantation (James and Salsbury, 1974) (Wexler, 1966 Spleen mass was determined in 2 groups of 8 mice 21 days after 1 ml of oral C. parvum or normal saline on Days 0, 3, 5 and 7 by immediate wreighing of the excised organ on a torsion balance. The histological appearances of spleens from such animals were compared by examination of haematoxylin and eosin stained sections.
Antibodies to C. parvumm were measured in 2 groups of 10 mice given 1 ml C. parurun 3 times weekly for 4 weeks. Controls were given appropriate doses of saline. Twelve days after the last dose of C. parvum the mice were heavily anaesthetized with ether and exsanguinated from the retro-orbital sinus. The serum was stored at -20°C and antibodies to C. Parruvn measured a week later by a passive agglutination technique. Doubling dilutions of serum wNere made in phosphate l)uffered saline to a total volume of 0 *2 ml in each tube. (If insufficient serum was available from individual mice, sera from 2 mice were pooled.) An equal volume of C. parruani diluted to the same opacitv as Browin's tube 2 (WN'ellcome) was added to the serum samples.
Positive and negative controls were included in the test. The mixtures were incubated for 2 h at 37°C and then at 4°C for 24-48 h. Agglutination was observed and the results expressed as titres.
RESULTS
The anti-tumour effects of 0 1 ml C. parvrtm administered i.v., i.p. or s.c. and given on the same day as tumour inoculation were studied in 3 groups of 9 mice. When compared with a group of 9 un- (Fig. 1 ) and the number of pulmonary metastases were less (Table I) . There was no significant effect of subcutaneous C. parvum on tumour size or metastases.
A dose of 1 ml of C. parvrnm given orally to 8 mice, 0, 3, 5 and 7 days after tumour inoculation had no effect upon the primary tumour (Fig. 2) or on the number of pulmonary metastases (Table II) (Table III) and the histological appearances of the spleens from these 2 groups of mice were similar. The antibody titre to (C. parvum in mice given i.v. (1* parvum was>1024. In mice given oral saline or C. parvurnt there was Ino significant difference in antibody titre, wAhich ranged from 32 to 1024.
DISCUSSION
Intravenous or intraperitoneal C. parvunt inhibited growith of the primary Lewis lung tumour and its metastases. This confirms the anti-tumour activity of C(. parvurn observed in other animal tumours (Woodruff and Boak, 1966); Halpern et al., 1966; Woodruff and Dunbar, 1973; Smith and Scott, 1972; Castro, 1974a) . No protective effect of C. parvurni, was observed when the same dose of C. parvumn was given subcutaneously and this confirms the inferior anti-tumour effects of the vaccine when given by this route Inchley, 1971 Woodruff, Inchley and Dunbar, 1972) . Further, there was no anti-tumour effect of oral C(. patvum despite the fact that the total dose given was 40 times that which had powerful anti-tuimour effects when administered i.v.
Spleen mass of mice given (7. parvunr i.v. or i.p. is increased 6-7-fold when compared with untreated controls (Castro, 1 974b) and there is a concomitant increase of mnacrophage function (Halpern et al., 1963) . When (. parvum was given orally in the same large dose there was no increase in spleen size.
WhenIC. parvurn is giveIn i.v. or i.p. antibodies develop against it, both in laboratory animals and humans. Mice given 0 1 ml C(. parvurtn i.v. showed an antibody titre greater than 1024. In mice given a total dose 120 times greater than the i.v. dosage there was no significant difference in effect from that in control mice receiving saline.
The observations that (. parvurm given orally does not initiate antibodies against itself, does not increase spleen size and does not have an anti-tumour effect against the Lewis lung tumouir in mice suggest that it is not absorbed intact across the gut wall. Therefore, we conclude that administration by this route is ineffective and will have no application to clinical practice.
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